Drug intelligence / Profile preview

AMP-029

Development stage: Preclinical
Lead developer: Amphastar France Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Subcutaneous, Intramuscular

Overview

AMP-029 is a preclinical-stage generic injectable drug candidate being developed by Amphastar France Pharmaceuticals, a subsidiary of Amphastar Pharmaceuticals. As of early 2026, the specific active pharmaceutical ingredient and therapeutic indications for AMP-029 have not been publicly disclosed. The candidate is part of Amphastar's broader pipeline of complex generic and proprietary injectable products, currently undergoing preclinical evaluation to support future regulatory filings.

Beyond the preview

Go deeper on AMP-029.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMP-029.

Explore the full profile